Comparative Pharmacology
Head-to-head clinical analysis: POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 IN PLASTIC CONTAINER versus SODIUM PHOSPHATES IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 IN PLASTIC CONTAINER versus SODIUM PHOSPHATES IN PLASTIC CONTAINER.
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER vs SODIUM PHOSPHATES IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium is the principal intracellular cation and is essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides calories and may prevent ketosis.
Sodium phosphates increase serum phosphate concentration, promoting renal excretion of calcium and phosphate, and inducing osmotic diarrhea to cleanse the colon.
Intravenous; typical adult dose is 10-20 mEq/hour, not exceeding 40 mEq/hour or 150 mEq/day, with continuous cardiac monitoring and serum potassium monitoring.
Oral: 30-90 mL (equivalent to 3.75-11.25 g sodium phosphate) once daily, preferably in the morning, with a full glass of water. Dose may be increased up to 240 mL per day in divided doses. Rectal enema: 118 mL (monobasic sodium phosphate 19 g, dibasic sodium phosphate 7 g) as a single dose.
None Documented
None Documented
The elimination half-life of potassium is not applicable in the traditional sense because potassium is an endogenous ion under tight homeostatic control. After intravenous infusion of a potassium load, the plasma concentration declines with a distribution phase of about 1-2 hours, followed by a slower elimination phase reflecting cellular uptake and renal excretion, with a terminal half-life of approximately 6-8 hours in patients with normal renal function.
Terminal half-life of absorbed phosphate is approximately 0.5–1 hour in patients with normal renal function. Clinically, effects on serum phosphate are transient and depend on renal clearance.
Renal: >90% of potassium intake is excreted by the kidneys, primarily via distal tubular secretion; fecal: <10%; minor sweat losses. In this formulation (KCl 0.22% in D5W), the potassium content is 2 mEq per 100 mL (approximately 20 mEq/L).
Primarily renal (≥90% as inorganic phosphate and sodium). Fecal elimination is minimal (<5%) via unabsorbed phosphate.
Category C
Category C
Electrolyte Supplement
Electrolyte Supplement